Navigation Links
New Data for Abbott's Investigational High Sensitive Troponin Test Shows It May Help Doctors Predict Heart Attack Risk
Date:7/30/2013

HOUSTON, July 30, 2013 /PRNewswire/ -- Abbott (NYSE: ABT) announced today promising results from a study evaluating its High Sensitive Troponin-I (hsTnI) assay presented at this year's American Association for Clinical Chemistry (AACC) annual meeting in Houston, Texas. The study, conducted by researchers at Brigham and Women's Hospital, demonstrated that Abbott's hsTnI test (currently for research-use only in the United States) may help doctors predict which patients presenting with symptoms of a heart attack, such as severe chest pain, are at a higher risk for having a heart attack 30 days later.

A concern for patients who present with severe chest pain is that they are more likely to experience another cardiovascular event within a few weeks or months. Researchers at Brigham and Women's Hospital evaluated the performance of a hsTnI assay (Abbott, ARCHITECT) with the performance of a fourth generation troponin T assay (Roche, TnT) among 4,695 patients presenting with severe chest pain and found that the hsTnI assay identified more patients at higher risk of recurrent heart attack, even at very low troponin concentrations.

"The ability to identify patients at higher risk for another heart attack or cardiovascular death is an essential step in their prevention," said Dr. Petr Jarolim, M.D., Ph.D., one of the key authors of the study and Medical Director, Clinical Chemistry and Laboratory Control, Brigham and Women's Hospital. "This study demonstrates that the new high sensitivity cardiac troponin assays are efficient tools for classifying patients, allowing doctors to provide more aggressive treatment of those at higher risk."

Cardiac troponin, a protein found in the heart muscle, is considered the preferred biomarker used to identify suspected heart attacks, because it can detect injury to the heart.1 Abbott's ARCHITECT STAT hsTnI assay can measure very low levels of the protein, which allows doctors to evaluate whether or not patients are having a heart attack within two to four hours after presentation.2 This faster evaluation could allow doctors to reduce the time to diagnosis and treatment by several hours when compared to standard troponin tests.

"This study adds to the clinical evidence confirming the advantages of Abbott's high sensitive troponin test to provide more insight to clinicians about which patients are at greater risk for a future heart attack as compared to contemporary tests," said John Frels, PhD, divisional vice president, Diagnostics Research, Abbott. "This is important information for patient care because it may help doctors focus on the patients at greater risk for appropriate management."

The abstract for this study was selected as the first annual recipient of the Biomarkers of Acute Cardiac Disease Division Outstanding Abstract Award. The committee awarded a grant for outstanding abstract to one of the key authors of the study, Dr. Petr Jarolim (Brigham and Women's Hospital).

The ARCHITECT STAT hsTnI assay is commercially available in Europe and runs on Abbott's fully-automated ARCHITECT family of analyzers.

About Abbott Diagnostics

Abbott is a global leader in in vitro diagnostics and offers a broad range of innovative instrument systems and tests for hospitals, reference labs, molecular labs, blood banks, physician offices and clinics. With more than 22,000 customers in more than 100 countries, Abbott's diagnostic products offer customers automation, convenience, bedside testing, cost effectiveness, and flexibility. Abbott has helped transform the practice of medical diagnosis from an art to a science through the company's commitment to improving patient care and lowering costs.

About Abbott

Abbott is a global healthcare company devoted to improving life through the development of products and technologies that span the breadth of healthcare. With a portfolio of leading, science-based offerings in diagnostics, medical devices, nutritionals and branded generic pharmaceuticals, Abbott serves people in more than 150 countries and employs approximately 70,000 people.

Visit Abbott at www.abbott.com and connect with us on Twitter at @AbbottNews.

1 Thygesen K, Alpert JS, Jaffe AS et al. Third universal definition of myocardial infarction. European Heart Journal. 2012; 33:2551-2567.

2 Abbott ARCHITECT STAT High Sensitive Troponin-I Product Insert (PI), January 2013.


'/>"/>
SOURCE Abbott
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Grifols Implements Its First Automated Inventory Management Carousel System for Investigational Pharmacies at Emory University
2. Signum Dermalogix Investigational New Drug (IND) Application Cleared by FDA: SIG990 a Potential Treatment for Rosacea
3. Sanofi Announces Positive Phase 3 Results for Investigational New Insulin U300
4. Phase III study finds investigational agent empagliflozin significantly reduced blood glucose in adults with type 2 diabetes and impaired kidney function
5. Phase III data show investigational compound empagliflozin significantly reduced blood glucose in adults with type 2 diabetes
6. Follow-up Phase II Data Analysis Adds to Body of Evidence for Investigational Novel Basal Insulin, LY2605541
7. Phase III data show significant reduction in blood glucose with investigational compound empagliflozin added to metformin or metformin plus sulfonylurea in adults with type 2 diabetes
8. Takeda Submits Biologics License Application for a New Investigational Drug Vedolizumab, in Moderately to Severely Active Crohns Disease and Ulcerative Colitis in the United States
9. Nektar Therapeutics Presents Positive Data from Human Abuse Liability Study for NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Pain, at 2013 Annual Meeting of The College on Problems of Drug Dependence
10. NeuroDerm Announces Presentation of Data from Studies Evaluating ND0612, an Investigational Levodopa Continuous Administration Drug, in Healthy Volunteers and in Patients with Advanced Parkinsons Disease
11. AbbVie Presents Preliminary Results from Phase I Study of Investigational Oncology Compound ABT-199/GDC-0199 in Patients with High-Risk Chronic Lymphocytic Leukemia (CLL) at European Hematology Association Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/22/2017)... , 22. März 2017   VWR ... weltweit tätige Anbieter von Produkten und Dienstleistungen ... Erwerb von EPL Archives Inc. bekannt, eines ... Kunden im kompletten Zyklus regulierter Forschung, Entwicklung ... Proben, Speicherung von Dokumenten und Zusatzdienstleistungen zur ...
(Date:3/22/2017)... March 22, 2017  Applied BioMath ( www.appliedbiomath.com ... drug research and development, today announced the latest ... Day 2017 is a day full of presentations, ... pharmacology (QSP) community. The focus is to learn ... and accelerating drug research and development. ...
(Date:3/22/2017)... March 22, 2017 National Medical Products ... received an Innovative Technology contract from Vizient, ... in the country. The contract was based on ... with expertise in this category who serve on ... Technology contracts for technologies that demonstrate an ability ...
Breaking Medicine Technology:
(Date:3/22/2017)... Los Angeles, California (PRWEB) , ... March 22, 2017 , ... ... has signed British boxing champ Ashley Theophane as a new Brand Ambassador. Theophane, who ... the British light welterweight title in 2011. He has racked up an impressive number ...
(Date:3/22/2017)... ... March 22, 2017 , ... ... that its digital marketing solutions have enabled Children’s Hospital of The King’s Daughters ... , Recognizing the value of a digital marketing approach, the 206-bed pediatric ...
(Date:3/22/2017)... ... March 22, 2017 , ... The Burke Medical Research Institute ... advances in basic neuroscience at the BMRI labs into new and improved treatments ... movement, vision, and cognition impaired by stroke, traumatic brain injury, cerebral palsy, and ...
(Date:3/22/2017)... ... March 22, 2017 , ... The Vanderbeck Agency, a ... greater Nassau County region, is embarking on a combined charity effort with the Great ... For the last 25 years, the Great Neck Breast Cancer Coalition has worked to ...
(Date:3/22/2017)... (PRWEB) , ... March 22, 2017 , ... Chris Humphrey ... to families and business professionals throughout the coastal plains region, is initiating a charity ... overcome cancer. , Dillyn was first diagnosed with leukemia on a Friday evening in ...
Breaking Medicine News(10 mins):